logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Proactive One2One Investor Forum May 2019

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), presents at the Proactive Investors One2One Investor Forum in London May 2019.

For more information visit www.silence-therapeutics.com

Quick facts: Silence Therapeutics PLC

Price: 362 GBX

AIM:SLN
Market: AIM
Market Cap: £283.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics CEO talks recent RNAi deals and updates on critical...

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses with Proactive London's Andrew Scott the recent deal between Novartis and The Medicines Company for its asset - the RNAi project inclisiran. Solomon also updates on their lead candidate, SLN124, which is being developed to treat...

on 28/11/19

RNS

Holding(s) in Company

3 days, 16 hours ago

Holding(s) in Company

1 week, 4 days ago

Holding(s) in Company

2 weeks, 1 day ago

Holding(s) in Company

2 weeks, 2 days ago

Holding(s) in Company

2 weeks, 3 days ago

Holding(s) in Company

4 weeks ago

Management Change

on 17/12/19

2 min read